Plasma Metabolomic Signature for Fast Biological Aging Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods to determine biological age are costly, time-intensive, and require specialized equipment and training, limiting their clinical utility in predicting physiological decline and disease risk.
Innovation Solution
Development of a plasma metabolomic signature that predicts biological aging using a weighted model based on clinical and physiological measures, allowing for a simple blood-based assay to identify individuals at risk for faster or slower aging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple clinical and physiological parameters are used to determine biological age, then prediction accuracy of disease risk is improved, but cost and time requirements increase substantially
Solution Approach 1:
The patent extracts a specific subset of metabolites from the complete metabolome that are most strongly associated with biological aging and disease risk. This metabolomic signature panel is a simplified version of the full metabolomic profile, containing only the most informative markers for predicting biological age and disease risk, thereby reducing assessment time and cost while maintaining prediction accuracy
Solution Approach 2:
The patent creates a surrogate blood-based metabolomic assay that copies and reflects the information contained in multiple clinical and physiological measurements. The metabolomic signature serves as a simplified proxy that captures the essential aging-related information from complex physiological assessments, enabling rapid prediction of biological age and disease risk through a single blood test
2Measurement precision
If multiple clinical and physiological parameters are used to determine biological age, then prediction accuracy of disease risk is improved, but equipment complexity and training requirements increase
Solution Approach 1:
The patent employs metabolomic profiling technology that can be performed on standard blood samples using widely available analytical platforms. The approach uses common metabolites that can be measured with routine laboratory equipment rather than requiring specialized long-lived biological samples or complex diagnostic devices, making the assay accessible in常规 clinical settings without extensive specialized training
Solution Approach 2:
The patent uses plasma metabolites as intermediary molecules that mediate between the complex physiological state and the measurement apparatus. These small molecule metabolites serve as accessible proxies that can be measured with standard analytical equipment, translating complex physiological information into a form that can be readily assessed with conventional laboratory tools
3Measurement precision
If comprehensive physiological assessments are performed to assess biological age, then accuracy in identifying individuals at risk for faster aging is improved, but clinical burden increases
Solution Approach 1:
The patent extracts the most critical aging-related information from comprehensive physiological assessments by focusing on a specific metabolomic signature in blood plasma. This signature contains the essential information needed to identify individuals at risk for faster aging, eliminating the need to perform multiple separate clinical and physiological tests while maintaining the ability to accurately identify at-risk individuals
Data Source
AI summary
Chronological age is an important predictor of morbidity and mortality, however it is unable to account for heterogeneity in the decline of physiological function and health with advancing age. Several attempts have been made to instead define a “biological age” using multiple physiological parameters in order to account for variation in the trajectory of human aging; however, these methods require technical expertise and are likely too time-intensive and costly to be implemented into clinical practice. Accordingly, a metabolomic signature of biological aging was developed that can predict changes in physiological function with the convenience of a blood sample. A weighted model of biological age was generated based on multiple clinical and physiological measures in a large group of healthy adults and was then applied to a cohort of healthy older adults who were tracked longitudinally over a 5-10 year timeframe. Plasma metabolomic signatures were identified that were associated with biological age, including some that could predict whether individuals would age at a faster or slower rate. These results not only have clinical implications by providing a simple blood-based assay of biological aging, but also provide insight into the molecular mechanisms underlying human healthspan.